Publications
- Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival +12021 | First Faculty of Medicine
- Intramuscular Interferon Beta-1a in combination with azathioprine and low-dose steroids for relapsing-remitting multiple sclerosis: design and preliminary results of a two-year double-blind, randomized, placebo-controlled studyPublication without faculty affiliation
- Tolerability of combine treatment with interferon beta and azathioprine in remitent MSPublication without faculty affiliation
- Interferon beta-1a in combination with azathioprine and low-dose steroids for relapsing-remitting multiple sclerosis: preliminary clinical and MRI data from a two-year, double-blind, randomized, placebo-controlled studyPublication without faculty affiliation
- Intramuscular Interferon beta-1a, Azathioprine, and corticosteroid combination therapy in patients with relapsing-remitting multiple sclerosis: 5-year clinical efficacy resultsPublication without faculty affiliation
- To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection2022 | First Faculty of Medicine
- Autoimmune diseases of the central nervous system in cases2017 | First Faculty of Medicine
- Two-year outcome of thymectomy with or without immunosuppressive treatment in nonthymomatous myasthenia gravis and its effect on regulatory T cells2015 | First Faculty of Medicine
- Advancements in symptomatic treatment of multiple sclerosis2012 | First Faculty of Medicine
- A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex (R)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis2011 | Publication without faculty affiliation
Loading network view...